Cargando…

Human plasma‐derived alpha(1)‐proteinase inhibitor in patients with new‐onset type 1 diabetes mellitus: A randomized, placebo‐controlled proof‐of‐concept study

BACKGROUND: While circulating levels of alpha(1)‐proteinase inhibitor (alpha(1)‐PI) are typically normal, antiprotease activity appears to be compromised in patients with Type 1 diabetes mellitus (T1DM). Because alpha(1)‐PI [human] (alpha(1)‐PI[h]) therapy can inhibit pro‐inflammatory mediators asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lagarde, William H., Courtney, Kecia L., Reiner, Barry, Steinmann, Kimberly, Tsalikian, Eva, Willi, Steven M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons A/S 2020
Materias:	Type 1 Diabetes: Pathophysiology and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984376/ https://www.ncbi.nlm.nih.gov/pubmed/33244872 http://dx.doi.org/10.1111/pedi.13162

Ejemplares similares

HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children
por: Salami, Falastin, et al.
Publicado: (2022)

Increased tissue factor activity promotes thrombin generation at type 1 diabetes onset in children
por: Jasser‐Nitsche, Hildegard, et al.
Publicado: (2020)

Extended family history of type 1 diabetes in HLA‐predisposed children with and without islet autoantibodies
por: Kuusela, Salla, et al.
Publicado: (2020)

Insulin resistance relates to DKA severity and affects insulin requirement in children with type 1 diabetes at onset
por: Mastromauro, Concetta, et al.
Publicado: (2022)

Celiac disease can be predicted by high levels of tissue transglutaminase antibodies in children and adolescents with type 1 diabetes
por: Cerqueiro Bybrant, Mara, et al.
Publicado: (2020)

Antibiotic treatment during early childhood and risk of type 1 diabetes in children: A national birth cohort study
por: Antvorskov, Julie Christine, et al.
Publicado: (2020)

Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results
por: Winkler, Christiane, et al.
Publicado: (2019)

Associations between deduced first islet specific autoantibody with sex, age at diagnosis and genetic risk factors in young children with type 1 diabetes
por: Ilonen, Jorma, et al.
Publicado: (2022)

Mixed‐meal tolerance test to assess residual beta‐cell secretion: Beyond the area‐under‐curve of plasma C‐peptide concentration
por: Ruan, Yue, et al.
Publicado: (2019)

Viral infection‐related gene upregulation in monocytes in children with signs of β‐cell autoimmunity
por: Valta, Milla, et al.
Publicado: (2022)

Type 1 Diabetes at a Crossroads!
por: Cefalu, William T., et al.
Publicado: (2015)

GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine?
por: Donath, Marc Y., et al.
Publicado: (2013)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Lower HbA1c in patients with type 1 diabetes and celiac disease who reached celiac‐specific antibody‐negativity—A multicenter DPV analysis
por: Nagl, Katrin, et al.
Publicado: (2019)

Genetic association analyses of atopic illness and proinflammatory cytokine genes with type 1 diabetes
por: Saleh, Nada M, et al.
Publicado: (2011)

Dietary Sugar and Body Weight: Have We Reached a Crisis in the Epidemic of Obesity and Diabetes?: Health Be Damned! Pour on the Sugar
por: Bray, George A., et al.
Publicado: (2014)

Size matters: Influence of center size on quality of diabetes control in children and adolescents with type 1 diabetes—A longitudinal analysis of the DPV cohort
por: Hackl, Lukas, et al.
Publicado: (2021)

Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: Raz, Itamar
Publicado: (2013)

Role of Reduced β-Cell Mass Versus Impaired β-Cell Function in the Pathogenesis of Type 2 Diabetes
por: Meier, Juris J., et al.
Publicado: (2013)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Genetic Screening for the Risk of Type 2 Diabetes: Worthless or valuable?
por: Lyssenko, Valeriya, et al.
Publicado: (2013)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
por: Strain, William David, et al.
Publicado: (2017)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Substitution among milk and yogurt products and the risk of incident type 2 diabetes in the EPIC‐NL cohort
por: Stuber, J. M., et al.
Publicado: (2020)

Effects of potato resistant starch intake on insulin sensitivity, related metabolic markers and appetite ratings in men and women at risk for type 2 diabetes: a pilot cross‐over randomised controlled trial
por: Sanders, L. M., et al.
Publicado: (2020)

Genetics of Autoimmune Thyroiditis in Type 1 Diabetes Reveals a Novel Association With DPB1*0201: Data From the Type 1 Diabetes Genetics Consortium
por: Kahles, Heinrich, et al.
Publicado: (2015)

Role of Type 1 Diabetes–Associated SNPs on Autoantibody Positivity in the Type 1 Diabetes Genetics Consortium: Overview
por: Rich, Stephen S., et al.
Publicado: (2015)

Changes in Zinc Transporter 8 Autoantibodies Following Type 1 Diabetes Onset: The Type 1 Diabetes Genetics Consortium Autoantibody Workshop
por: Wenzlau, Janet M., et al.
Publicado: (2015)

Shared Genetic Basis for Type 1 Diabetes, Islet Autoantibodies, and Autoantibodies Associated With Other Immune-Mediated Diseases in Families With Type 1 Diabetes
por: Brorsson, Caroline A., et al.
Publicado: (2015)

Summary of the Type 1 Diabetes Genetics Consortium Autoantibody Workshop
por: Rich, Stephen S., et al.
Publicado: (2015)

Severe Scratching in Spinocerebellar Ataxia 17: Another Case
por: Pauly, Martje G., et al.
Publicado: (2020)

Clinical Spectrum of Drug-Induced Movement Disorders: A Study of 97 Patients
por: Gupta, Harsh V., et al.
Publicado: (2020)

Late-Onset Tay-Sachs Disease - expanding the clinical phenotype
por: Lefter, Stela, et al.
Publicado: (2023)

Contrasting the Genetic Background of Type 1 Diabetes and Celiac Disease Autoimmunity
por: Gutierrez-Achury, Javier, et al.
Publicado: (2015)

Design and Measurement of Nonislet-Specific Autoantibodies for the Type 1 Diabetes Genetics Consortium Autoantibody Workshop
por: Akolkar, Beena, et al.
Publicado: (2015)

ATPase4A Autoreactivity and Its Association With Autoimmune Phenotypes in the Type 1 Diabetes Genetics Consortium Study
por: Wenzlau, Janet M., et al.
Publicado: (2015)

SirT1 Regulates Adipose Tissue Inflammation
por: Gillum, Matthew P., et al.
Publicado: (2011)

Novel Role of the IGF-1 Receptor in Endothelial Function and Repair: Studies in Endothelium-Targeted IGF-1 Receptor Transgenic Mice
por: Imrie, Helen, et al.
Publicado: (2012)

Inflammation and Hyperglycemia Mediate Deaf1 Splicing in the Pancreatic Lymph Nodes via Distinct Pathways During Type 1 Diabetes
por: Yip, Linda, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_or1gmuen4emou9igh8uukenlo3